Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis.
A systematic review compares different drug combinations for bladder cancer before surgery, helping clinicians weigh options as new treatments emerge.
With multiple neoadjuvant regimens now available or in trials for MIBC, this meta-analysis provides a systematic comparative framework for EV-based vs ICI-only approaches in terms of pathological complete response and perioperative outcomes. The synthesis is timely given FDA approvals for EV+pembrolizumab and the active clinical decision-making landscape for MIBC, though meta-analysis design inherently limits causal inference.
What the study was
- Study design
- systematic_review_meta_analysis
- Population
- Muscle-invasive bladder cancer
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Urologic Oncology
Why it surfaced
EV+pembrolizumab is an FDA-approved combination with rapidly expanding use in bladder cancer; neoadjuvant MIBC is a high-enrollment phase II/III space; meta-analysis from an NCC Japan group synthesizing current evidence provides useful comparative benchmarks for pipeline and trial design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.